Rationale: Heightened cough responses to inhaled capsaicin, a transient receptor potential vanilloid 1 (TRPV1) agonist, are characteristic of patients with chronic cough. However, previously, a TRPV1 antagonist (SB-705498) failed to improve spontaneous cough frequency in these patients, despite small reductions in capsaicinevoked cough.
Chronic cough (.8 wk in duration) is thought to affect approximately 12% of the population (1) . Patients presenting with isolated chronic cough (with normal chest radiography and spirometry) frequently report that coughing is associated sensations of throat irritation and an urge to cough, which are triggered by trivial exposures to environmental irritant chemicals, temperature changes, and use of their voice (2, 3) . These clinical features are suggestive of a hyperexcitability of the neuronal pathways responsible for controlling cough. Consistent with this hypothesis, heightened cough responses to inhaled irritants, most commonly capsaicin, have been shown to be a characteristic feature in such patients (4) (5) (6) .
The cough reflex is regulated by vagal afferent nerves that innervate the airway. Some are more mechanically sensitive, and some are more chemosensitive, such as C-fibers and Ad-nociceptors (7) . Ion channels present on these vagal nerve termini can be activated by a wide variety of stimuli to elicit cough. The main family of ion channels implicated in the initiation of sensory reflexes are transient receptor potential (TRP) channels (7) . Transient receptor potential vanilloid 1 (TRPV1) is a polymodal ion channel and was the first to be identified. It is activated by diverse stimuli, including the direct activators capsaicin (constituent of chili peppers from piquant Capsicum spp. plants), noxious heat greater than 42 8 C, and acidic conditions/protons that interact directly with the channel to cause a lowering of its voltage dependency, leading to opening of the pore domain (8) . It can also be activated indirectly by endogenous "disease-relevant" mediators, including bradykinin and prostaglandin E 2 (9, 10) .
Capsaicin reliably activates the cough reflex in several species, including humans, and is a specific TRPV1 agonist (10) (11) (12) (13) . TRPV1 is expressed by vagal afferent C-and Ad-nociceptive fibers innervating the airways (7) . Capsaicin is the most frequently used agent for experimentally inducing cough in preclinical and clinical studies, where the concentration of capsaicin evoking at least five coughs (C5) is the traditional endpoint. Numerous studies have demonstrated lower capsaicin C5 in subjects with chronic cough compared with healthy control subjects (i.e., the cough reflex is more sensitive), suggesting that TRPV1 could be an important treatment target (4, 5) . However, on the basis of clinical cough challenges, it cannot be determined whether this lowering of the cough threshold is related to changes in TRPV1 at the sensory nerve terminals or in central pathways.
Only one previous clinical study has evaluated the antitussive effects of a single dose of a TRPV1 antagonist (SB-705498) in patients with refractory chronic cough (12) . However, disappointingly, there was no effect on spontaneous cough frequency, although there was a small but statistically significant impact on the capsaicin C5 (increased by approximately one doubling dose over placebo), giving some evidence of target engagement. These data therefore questioned the role of TRPV1-mediated mechanisms in patients with refractory chronic cough; however, it remained unclear whether more potent antagonists and/or more prolonged dosing might still be efficacious. XEN-0501 is a potent and safe TRPV1 antagonist. It has demonstrated subnanomolar potency for TRPV1 receptors in human and rat recombinant cell systems and rat cultured dorsal root ganglia neurons, and its selectivity has been confirmed against panels of enzymes, ion channels, and G protein-coupled receptors (14) . Thus, the aims of this study were first to compare a potent TRPV1 antagonist (XEN-D0501) with SB-705498 in preclinical studies to establish whether an improved efficacy profile would support a further clinical trial. Second, we sought to evaluate the antitussive effect of XEN-D0501 in a double-blind, randomized controlled trial in patients with refractory chronic cough. Some of the results of these studies were previously reported in the form of an abstract (15) .
Methods
For detailed methods, see the online supplement.
Preclinical Studies
Animals. In vivo and ex vivo experiments were conducted with male Dunkin-Hartley guinea pigs (300-500 g) (Harlan Ltd., Bicester, UK; B&K Universal, Hull, UK). The experiments were performed in accordance with the U.K. Home Office guidelines for animal welfare based on the Animals (Scientific Procedures) Act 1986 and the Animals in Research: Reporting In Vivo Experiments guidelines (16) .
Guinea pig and human isolated vagus nerve recording. Recording of depolarization (as a measure of vagal, afferent sensory nerve activity) of isolated guinea pig and human vagus nerves was performed as described previously (9, 17, 18) . Briefly, nerves were stimulated twice with capsaicin (1 mM) for 2 minutes before vehicle or XEN-D0501 (0.1-100 nM) or SB-705498 (1-10 mM) was perfused for 10 minutes. The response to capsaicin (1 mM) was then reassessed in the presence of vehicle or test compounds. After a 10-minute washout, nerves were finally stimulated again with capsaicin (1 mM) to confirm viability.
Human en bloc lungs unsuitable for transplant were obtained from the International Institute for the Advancement of Medicine (Edison, NJ), and vagal tissue was obtained (n = 4, 36-57 yr old, 3 males). In all cases, consent was obtained for tissue for use in scientific research. Ethics approval was obtained from the Royal Brompton & Harefield NHS Foundation Trust.
Capsaicin-evoked cough in guinea pigs.
Vehicle (0.5% methylcellulose, 0.1% Tween 80, 5 ml/kg, intraperitoneal administration), XEN-D0501 (1-10 mg/kg, intraperitoneal
At a Glance Commentary
Scientific Knowledge on the Subject: Conclusive data regarding the importance of transient receptor potential vanilloid 1 (TRPV1) as a treatment target in chronic cough has been lacking because of the absence of a safe, potent, and efficacious compound for use in clinical studies. In a previous study, a TRPV1 antagonist (SB-705498) failed to improve spontaneous cough frequency in treatment-resistant chronic cough patients, but the reduction in capsaicin-evoked cough was only small.
What This Study Adds to the
Field: This study rules out TRPV1 as an effective therapeutic target in patients with refractory chronic cough. It also highlights the importance of pharmacodynamic preclinical and clinical models in the interpretation of negative clinical trial data, but it questions the use of cough challenge models in target identification. administration), or SB-705498 (10-100 mg/kg, intraperitoneal administration) was administered 1 hour prior to cough recording. Conscious, unrestrained guinea pigs were placed in individual plastic transparent whole-body plethysmograph chambers (Buxco Research Systems, Wilmington, NC); cough was assessed to an aerosol of capsaicin (60 mM in 1% ethanol, 1% Tween 80 in 0.9% sterile saline for 5 minutes); and coughs were counted for 10 minutes as previously described (9, 18) . Studies were also performed to establish if the XEN-D0501 compound retained efficacy after repeat dosing. In these studies, guinea pigs were dosed with vehicle (0.5% methylcellulose, 0.1% Tween 80, 5 ml/kg, intraperitoneal administration) or compound (1 or 3 mg/kg twice daily) for 13 days and then 1 hour prior to cough assessment. Capsaicin-induced cough was then assessed as previously.
Clinical Study
Study design. A double-blind, randomized, placebo-controlled crossover study was performed to evaluate the antitussive efficacy of 14-day treatment with XEN-D0501 (oral 4 mg twice daily) compared with matched placebo; the two treatment periods were separated by a 14-day washout ( Figure 1A ). Participants were recruited from two specialist cough clinics (University Hospital of South Manchester, Manchester, UK; and Belfast City Hospital, Belfast, UK) between July 2014 and June 2015. Cough was assessed prior to dosing and at the end of each treatment period using an ambulatory cough monitor and patient-reported outcomes. Capsaicin-evoked cough responses were included as a pharmacodynamic endpoint.
Participants. We recruited subjects with refractory chronic cough, as determined by U.K. national cough guidelines issued by the British Thoracic Society (19) . An awake cough frequency of more than 1.5 coughs/h and a maximal capsaicin cough response over four inhalations (E max ) of more than 10 coughs were required for inclusion to avoid including patients with very low cough frequency/ capsaicin-evoked cough responses, in whom a treatment effect would be difficult to demonstrate. Current smokers and ex-smokers with a smoking history of greater than 20 pack-years were ineligible, as were women of childbearing potential and those taking treatments that may modulate cough (e.g., morphine, gabapentin). The study was approved by an independent research ethics committee (REC North West-Liverpool East reference 14/NW/0211), and all patients gave written informed consent.
Study treatment, randomization, and masking. Patients were assigned to one of the two possible treatment sequences by a computer-generated randomization schedule with a ratio of 1:1 for XEN-D0501/placebo or placebo/XEN-D0501. Patients, health-care providers, investigators, and the sponsor were all masked to the treatment sequence assignment. The dose of XEN-D0501 used in this study (4 mg twice daily) was considered to be the maximum tolerable dose in the older age group of patients typically presenting with chronic cough.
Procedures. Patient demographics, treatments, and comorbidities were collected at screening. Cough was assessed at four time points; for both treatment periods, this was prior to dosing and at the end of the treatment period ( Figure 1A ). Safety was assessed through monitoring of vital signs, ECGs, body temperature, hematology, biochemistry, and adverse events (AEs).
Outcomes. The primary endpoint was awake objective cough frequency collected using a 24-hour ambulatory cough monitor commenced at Day 0 and Day 13 of each treatment period; sleep and 24-hour cough frequency were also determined. The secondary endpoints included changes from baseline on a 100-mm cough severity visual analogue scale (VAS), a cough-specific quality-of-life questionnaire, and a 15-point global rating of change scale for cough severity and frequency, completed at the end of each treatment period. Cough responses to inhaled capsaicin provided a pharmacodynamic endpoint and were assessed on Days 1 and 14 following completion of each 24-hour cough recording.
Twenty-four-hour acoustic recordings were made using the VitaloJAK cough monitor (Vitalograph Ltd., Maids Moreton, UK) with cough sounds per hour quantified by a semiautomated method using validated, custom-written software (12, 20, 21) .
COUGH CHALLENGES. Four breaths of doubling concentrations of capsaicin (0.97-1,000 mM; Stockport Pharmaceuticals Ltd., Stockport, UK) were inhaled at 1-minute intervals from a dosimeter (KoKo dosimeter; DeVilbiss Healthcare Inc., Somerset, PA). The number of coughs in the 15 seconds following each inhalation was counted. The challenge continued until the maximum tolerated dose or the final concentration was inhaled (6, 22) . The maximum number of coughs evoked at any concentration (E max ) was the main endpoint, but the concentration evoking 50% of the maximal response (mean effective dose [ED 50 ]) was also reported. To allow comparison with previous studies, the concentrations of capsaicin evoking two (C2) and five (C5) endpoints were also extracted from the cough challenge data for analysis.
PATIENT-REPORTED COUGH MEASURES.
Subjects rated cough severity and urge to cough on separate 100-mm VASs for daytime and nighttime. Cough-specific quality of life was assessed using the Leicester Cough Questionnaire; higher scores indicated better quality of life (23) .
Data Analysis
Vagal depolarization. Inhibition of depolarization was analyzed using a paired t test, given that observations were made using the tissue as its own control. Data presented are mean 6 SEM, with statistical significance set at a value of P , 0.05.
Cough. Inhibition of cough by the TRPV1 antagonists in vivo was analyzed initially using a Bartlett's test to determine whether the variances were equal and then either a parametric test (analysis of variance followed by a Bonferroni's multiple comparison test) or a nonparametric test (Kruskal-Wallis followed by Dunn's multiple comparison test) to compare responses from the antagonist group with those from the vehicle control group. Data presented are mean 6 SEM, with statistical significance set at a value of P , 0.05.
Clinical study. Sample size was estimated on the basis of previous data (awake cough frequency, approximately 25 coughs/h; log 10 SD, 0.23-0.41). On the basis of these assumptions, 16 patients would be needed to detect a 56% reduction in awake cough frequency (90% power; 5% significance level). The change from baseline in the awake objective cough frequency was analyzed with a mixed effects linear model, with baseline and treatment period as fixed effects and patient as a random effect. Awake cough frequency was log transformed for analysis, and the standard P , 0.05 level of significance was applied. Similar models were applied to the secondary endpoints, with or without logarithmic transformation as appropriate.
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Results
Preclinical Studies
Guinea pig and human vagus nerve depolarization. XEN-D0501 (0.1-100 nM) inhibited capsaicin-induced depolarization of the guinea pig vagus nerve in the nanomolar range in a concentrationdependent manner with a maximal inhibition of 87.2 6 4.4% at 10 nM (Figure 2A) . The maximally effective concentration of XEN-D0501 (10 nM) had no effect on responses to the TRPA1 agonist acrolein (300 mM), indicating no off-target activity on another TRP channel expressed on C-fiber afferents, which, when activated, are also known to evoke cough in guinea pigs and humans (24) . SB-705498 (1-10 mM) also evoked a concentrationdependent inhibition of capsaicin-induced A second patient was withdrawn during placebo dosing because the patient was found to have been included in the study in error. BID = twice daily.
depolarization of guinea pig vagus nerve that was in the micromolar range with a maximal inhibition of 52.4 6 5.5% at 10 mM ( Figure 2B ). Higher concentrations could not be formulated for in vitro experiments, because solubility was compromised. Similarly, XEN-D0501 (0.1-100 nM) also inhibited capsaicininduced depolarization of the human vagus nerve in the nanomolar range in a concentration-dependent manner with 80.54 6 10.4% at 100 nM ( Figure 2C) . Furthermore, consistent with data generated in the guinea pig, SB-705498 inhibited depolarization in the micromolar range. Figure 3A) . SB-705498 significantly inhibited cough only at the highest dose tested (vehicle, 6.71 6 1.9 coughs/10 min; XEN-D0501 100 mg/kg, 0.29 6 0.29 coughs/10 min; n = 7) ( Figure 3B ). XEN-D0501 retained its efficacy following 13 days of twice-daily dosing, inhibiting capsaicin-evoked cough to the same extent as in guinea pigs receiving only a single dose 1 hour prior to the cough challenge ( Figure 3C ).
Clinical Study
Subjects. Twenty patients with refractory chronic cough (mean age, 63.1 yr; 15 females) were recruited (see Table 1 and Figure 1B ). Patients were typical of those attending specialist cough clinics, and those randomized to each treatment sequence were well matched. Two patients discontinued study treatment and withdrew from the study. One patient was withdrawn during XEN-D0501 treatment because of a treatment-emergent adverse event (TEAE) of fatigue considered related to study treatment. Another patient was withdrawn during placebo dosing because the patient did not meet all the inclusion criteria and was included in error. A tablet count suggested that compliance with study treatment was high and almost identical for XEN-D0501 and placebo. Over the 2-week treatment periods, this suggested subjects consumed a mean of 26.7 XEN-D0501 tablets (95% confidence interval, 26.5-27.5) and a mean of 27.0 (95% confidence interval, 25.9-27.5) placebo tablets (P = 0.56).
Cough frequency and capsaicin-evoked cough responses. Consistent with the preclinical data, XEN-D0501 dramatically reduced maximal cough responses to capsaicin (E max mean difference, XEN-D0501, 219.3 6 16.4 coughs; placebo, 21.8 6 5.8 coughs; P , 0.0001) (Figure 4) . The logC2 and logC5 endpoints also significantly improved from baseline with XEN-D0501; increases in logC2 of 11.10 mM (SEM, 60.34; P = 0.005) and in logC5 of 11.22 mM (SEM, 60.40; P = 0.007) over placebo, equivalent to increases of 13.7 and 14.1 doubling doses of capsaicin, respectively. However, there was no difference in the change from baseline in spontaneous daytime cough frequency for treatment with XEN-D0501 compared with placebo (awake cough frequency mean change, XEN-D0501, 6.7 6 16.9 coughs/h; placebo, 0.4 6 13.7 coughs/h; P = 0.41) ( Table 2) 
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hourly cough counts on Day 14 of treatment with placebo and XEN-D0501 are shown in Figure 5 . Treatment sequence and period had no significant effect in any of these analyses.
Patient-reported outcomes. Overall, the patient-reported endpoints did not suggest that patients perceived significant improvements in their cough. The only exception was awake cough severity VAS, which improved with placebo treatment compared with XEN-D0501, although the magnitude of the difference was very small indeed (mean difference, 2.8 mm; SD, 621.4; P = 0.03). Again, treatment sequence and period had no significant effect in any of the analyses.
Safety and AEs. No serious AEs were reported during the study. In total, 103 TEAEs were reported by 18 (94.7%) patients receiving XEN-D0501; 89 events were considered to be treatment related. Fourteen AEs were reported by 9 (47.4%) patients receiving placebo, of which 5 events were considered treatment related. The most frequently reported AEs were related to temperature sensations or mouth-related events and were consistent with those seen in previous studies (14) . The most common AEs, reported by at least patients taking XEN-D0501 were thermohypoesthesia (n = 8), dysgeusia (n = 9), feeling of body temperature change (n = 6), feeling hot (n = 3), oral paresthesia (n = 3), and hyperhidrosis (n = 3). Headache was also a frequently reported TEAE (n = 3 taking XEN-D0501 and n = 1 taking placebo). No concerns were raised by other measures of safety (i.e., ECGs; vital signs including body temperature; physical examination findings; and routine hematology and coagulation, clinical chemistry, and urinalysis assessments).
Discussion
Cough is the most common condition for which patients seek medical attention, but currently there are no licensed treatments for refractory chronic cough, and evidence is lacking to suggest that over-the-counter cough medications are effective (25) . The cough reflex is regulated by vagal afferent nerves that innervate the airway, some of which are more mechanically sensitive (the rapidly adapting receptors, slowly adapting receptors, and the subtype known as the "cough" receptor), and some of which are more chemosensitive (C-fibers and Ad-nociceptors) (7) . Ion channels present on these vagal nerve termini can be activated by a wide variety of stimuli to elicit cough and other reflexes. The main family of ion channels implicated in the initiation of sensory reflexes is the TRP channels (7). A significant amount of information has been gathered regarding the biology of TRPV1 from clinical capsaicin challenge studies. Interestingly, the threshold for provoking cough by capsaicin (C2 or the C5 concentration of capsaicin required to elicit at least two or five coughs, respectively) has been found to be lowered in various populations of patients with chronic obstructive pulmonary disease (4, 26) , asthma (22, 26) , idiopathic pulmonary fibrosis (27) , and refractory chronic cough (4, 5, 28) compared with healthy control subjects. These data imply that TRPV1 function is frequently increased in a disease setting. However, it is still not certain if increased sensitivity to various challenge agents acting on particular ion channels informs us regarding whether a particular intervention will be useful in a certain disease setting. In one of the studies cited above, different patient groups (chronic obstructive pulmonary disease, healthy smokers, refractory chronic cough, and asthma) were compared and exhibited different patterns of modulation of cough responses to a range of inhaled irritants (4) . These data support the concept of diseasespecific neurophenotypes in airway disease, suggesting that chronic cough associated with different etiologies may not be sensitive to similar interventions.
Of all the TRP channels, antagonists for TRPV1 are the most advanced with regard to drug development and clinical trials. However, development of these inhibitors has not been straightforward, owing to the activity of TRPV1 as a thermosensor for hot temperatures. This has seen several TRPV1 antagonists fail to progress, owing to adverse effects such as increased body temperature and latent withdrawal to noxious hot stimuli. For instance, AMG 517 caused significant and long-lasting increases in body temperature in phase I clinical trials in patients following molar extractions. In that case, the trial was terminated before any efficacy, in relation to possible analgesic effects, could be determined (29) . Other compounds also trialed in dental pain studies exhibited similar AEs, with increases in body temperature and altered noxious heat sensation. In all cases, these AEs were correlated with target engagement. More recently, compounds have been identified that are not limited because of AEs.
SB-705498 has been reported to be a potent, selective, orally bioavailable, competitive TRPV1 receptor antagonist that does not exhibit significant disturbances in temperature perception or control (30) . The availability of safe, "clinical-ready" TRPV1 antagonists has already allowed the profiling of SB-705498 in a double-blind randomized controlled trial in patients with refractory chronic cough (12) . That trial used objective cough monitoring and capsaicin challenge as a pharmacodynamic marker of target engagement, and reported that a single dose of SB-705498 was well tolerated with no significant increase in tympanic temperature or reported temperature perception. However, disappointingly, SB-705498 lacked efficacy in improving spontaneous cough frequency in patients with refractory chronic cough, although there was a small but statistically significant shift in capsaicinevoked cough. Pharmacodynamic modeling estimated SB-705498 receptor occupancy to be 45% at 2 hours (associated with more than a doubling dose shift in C5 values over placebo) and 25% at 24 hours (associated with a 0.7 doubling dose shift in C5 values over placebo). Therefore, it was not clear whether the lack of efficacy in reducing spontaneous cough was due to the modest receptor occupancy and whether a compound with increased potency and efficacy at reducing cough in response to capsaicin would be required. Furthermore, the long half-life of SB-705498 (50-60 h) limited previous clinical studies of this drug to investigating the efficacy of single doses, and therefore the potential effects of more prolonged TRPV1 blockade could not be determined.
In these experiments, we used a potent and selective TRPV1 receptor antagonist, XEN-D0501, that has been shown to demonstrate subnanomolar potency in human recombinant cellular systems and rat dorsal root ganglia neuron preparations. In a phase I safety study, XEN-D0501 was well tolerated with repeat dosing, with no serious AEs and a slight increase in core body temperature that attenuated over time and was not considered to be of clinical concern (14) . In this study, we demonstrate superior However, one might expect a 10-fold or greater dropoff in potency when one looks at the activity against the native ion channel in a tissue-based assay. In vivo XEN-D0501 (1 mg/kg) completely inhibited capsaicin-induced cough, whereas 100 times more SB705498 (100 mg/kg) was required to achieve the same effect, which was somewhat consistent with previous data demonstrating some inhibition with SB-705498 (at 10 and 30 mg/kg) in a capsaicin-induced secondary hyperalgesia model in the rat (31) . In this study, target engagement was demonstrated in preclinical and clinical studies, with XEN-D0501 blocking the cough in response to capsaicin observed in both models, highlighting the translational capacity of the guinea pig model. Rather than the traditional clinical C5 endpoint, which is somewhat arbitrary, we used novel cough challenge methodology that captures the dose-response relationship between capsaicin and cough using the pharmacodynamic endpoints E max and ED 50 (6) . We have recently shown that E max better discriminates patients with chronic cough from healthy control subjects and patients with mild asthma, and it is more readily compared with preclinical cough studies. E max exhibited substantial improvements in this study. However, this did not translate into efficacy for XEN-D0501 on spontaneous coughing in patients with chronic cough.
This study has some limitations; as a proof-of-concept study, the sample size was small. Nonetheless, significant changes in capsaicin cough responses were still clearly demonstrated. Furthermore, both our power calculations and those of previous studies demonstrate that objective cough monitoring is a powerful tool for demonstrating efficacy, and large studies are not required (21) . It should also be acknowledged that although no serious AEs or changes in body temperature occurred in this study, TRPV1 antagonism was still associated with frequent nonsevere AEs, mainly relating to temperature sensing, perceived body temperature, and alterations in taste.
In summary, the fact that potent TRPV1 antagonism, producing considerable reductions in capsaicin-evoked cough, was not associated with any improvements in objective cough frequency suggests that TRPV1 is not an effective target in refractory chronic cough. This is in stark contrast to recent demonstrations of the efficacy of P2X3 antagonism, implicating this ion channel and its endogenous ligand, ATP, in the mechanisms underpinning chronic cough (20) . The present study may also provide an indication that increased sensitivity to one mechanism (e.g., TRPV1), demonstrated by challenge studies (e.g., using capsaicin) in one patient group (refractory chronic cough), does not necessarily implicate the utility of said target in a particular patient group. However, this may not be the case for TRPV1 in other conditions that exhibit chronic cough or with other TRP channels involved in chronic cough. What this study does illustrate is that challenge paradigms across preclinical and clinical models can deliver effective pharmacodynamic models that can inform dosing regimens in future clinical trials across any therapeutic area. n Author disclosures are available with the text of this article at www.atsjournals.org.
